|Articles|August 23, 2021

Integrated Inhaled Dose Development

Author(s)Catalent

With more than 30 years’ experience, Catalent offers end-to-end solutions for multiple inhalation dose forms.

With more than 30 years of experience in supporting the development of inhaled products, and full commercial-scale manufacturing capabilities for dry powder inhalers, metered dose inhalers and unit/bi-dose nasal sprays, Catalent offers complete, end-to-end solutions for today’s inhalation dose forms.

Catalent provides formulation feasibility, device selection and clinical supply services, through to commercial filling and packaging, as well as analytical testing, final product characterization and release testing to ensure accurate, consistent drug delivery.

URL: https://www.catalent.com/specialty/inhalation/

Catalent Pharma Solutions
14 Schoolhouse Road Somerset, NJ 08873 USA
Tel. +1.888.765.8846
solutions@catalent.com
www.catalent.com


Related to this article

Are Your Supplier Selection and Oversight Processes Robust Enough?
Despite best efforts to ensure a contract organization is following GMPs, a warning letter is issued by the FDA. Susan J. Schniepp, distinguished fellow at Nelson Labs, and Siegfried Schmitt, PhD, vice president, Technical at Parexel, provide advice for create a robust supplier selection and oversight system.
white pill capsule isolated on white background | Image Credit: ©F16-ISO100 -stock.adobe.com
PharmTech spoke with Chiara Bergerone, deputy CEO of Roquette’s Health & Pharma Solutions Business, about the company’s hydroxypropyl methylcellulose (HPMC) capsule, which was previewed at CPHI Milan 2026 in October.
Transitioning mRNA from R&D to GMP
Marco Pupo, PhD, innovation and development coordinator at Anemocyte, discusses the R&D-to-GMP transition and the changing shape of mRNA manufacturing facilities.